Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$4.94
-$0.03(-0.57%)
At close: 4:00 PM EDT
$4.94
-$0.03(-0.57%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume52.26K
Average Volume (3M)42.85K
Market Cap
$35.54M
Enterprise Value$71.31M
Total Cash (Recent Filing)$10.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Dec 11, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding13,511,531
10 Day Avg. Volume49,614
30 Day Avg. Volume42,853
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-693.39
Enterprise Value/Ebitda-4.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageEffectively zero debt reduces solvency and interest-burden risk while preserving financial flexibility for clinical development. Although the company remains loss-making, its low leverage means fewer obligations compete with research spending and future financing needs.
EB06 Clinical AdvancementFDA clearance is a structural development that expands EB06 recruitment beyond Canada and advances the lead program into a broader Phase 2 study. U.S. site access can support trial execution and create a clearer path toward generating clinical value.
Targeted Pipeline ApproachEB06 uses a defined targeted mechanism aimed at disrupting immune-cell recruitment and melanocyte loss, rather than broad immunomodulation. This gives Edesa a focused clinical thesis in an unmet-need indication and a basis for potential differentiation if efficacy and safety are demonstrated.
Bears Say
No Operating RevenueZero revenue means Edesa has not yet established an operating business capable of funding itself. The company therefore remains dependent on successful clinical development and eventual commercialization, leaving near-term financial performance disconnected from product demand or recurring customer income.
Persistent Cash BurnOngoing operating and free-cash-flow deficits show that research activities consume substantial cash without internally generated funding. This dependence on external capital can constrain development plans over time and exposes the company to financing needs before clinical programs produce revenue.
Sustained Losses And Capital VolatilityLarge recurring losses and materially changing equity indicate that shareholder capital has not yet produced profitable returns and may be affected by financing activity. Continued negative ROE and volatile results weaken financial resilience while the pipeline remains pre-revenue.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Edesa Biotech Inc’s market cap is $35.54M.
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is Dec 11, 2026 which is in 43 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Aug 13, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.165.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Overvalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -0.58.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 13,511,531 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -1.473%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EDSA Sentiment 100%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-124.21%
Trailing 12-Months
Asset Growth
-14.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Edesa Biotech Inc
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Technical Analysis
Instil Bio
―
TScan Therapeutics
―
MiNK Therapeutics
―
Xilio Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
15.46% Insiders
0.93% Mutual Funds
20.26% Other Institutional Investors
62.75% Public Companies and
Individual Investors